The Colonnade Hotel
120 Huntington Ave
Advancing ICI-containing IO-combination therapies is central to getting the full therapeutic benefit out of ICIs. Selecting the right combination partners and strategies are essential to the making the correct decision.
This industry-led meeting will focus on how the response rate to checkpoint combinations can be enhanced to impact every stage of the cancer immunity cycle, as well as shed light on the specific challenges that come with combining IO therapies with ICIs.
Through interactive workshops, panel discussions and roundtables, this is a great opportunity to gain practical implementable insight into IO combo development strategy.